Posts

Posted on

Getty Images and UEFA Renew Multi-Year Agreement

Getty Images and UEFA Renew Multi-Year Agreement

A Media Snippet accompanying this announcement is available by clicking on this link.

LONDON, March 03, 2025 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced it has renewed its multi-year partnership with UEFA, with Getty Images continuing to serve as UEFA’s official appointed photographic agency.

The agreement will see Getty Images’ award-winning sports photographers and editors provide comprehensive coverage of all UEFA men’s and women’s club and national team competitions, including the UEFA Champions League, UEFA Europa League, the new UEFA Women’s Europa Cup starting in the 2025/2026 season, and the UEFA Futsal EURO.

Alongside its matchday coverage of the UEFA Champions League, Getty Images will provide UEFA and its commercial partners with an expanded range of creative editorial content including official player portraits of all 36 UEFA Champions League teams, while continuing to supply portraits of all clubs competing in the UEFA Women’s Champions League. The team at Getty Images will also provide short-form video content services for UEFA partners, capturing the atmosphere and brand production at UEFA Champions League matches.

“We are proud to build on the two-decades-long relationship between Getty Images and UEFA, where we continue to support UEFA and its partners with fresh, creative and engaging imagery delivered in almost real-time to drive the fan experience,” said Michael Heiman, Vice President of Global Sport at Getty Images. “Our industry-leading sports photographers relish the opportunity to capture the iconic moments of Europe’s biggest football tournaments in imagery available via the UEFA Collection.”

Getty Images will serve as the official appointed photographic agency for the upcoming UEFA Women’s EURO 2025 in Switzerland, with its photographers covering every angle of the tournament across eight cities from the Opening Match on 2 July to the Final on 27 July. Its assigned UEFA photographers will capture official player and squad portraits, atmospheric imagery of the fans around the country, match action, and portraits of the winning team taken immediately after the final whistle.

“We are delighted to continue our long-standing partnership with Getty Images, whose photographers have consistently delivered high-quality content and captured unforgettable moments for our channels and those of our partners over the years,” comments Phillip Williams, Head of Editorial Content Services at UEFA.

For 30 years, Getty Images has been a trusted partner to many of the world’s leading sports rights holders. In addition to its work with UEFA, Getty Images is the official photographer or photographic partner to 125 of the most significant sports governing bodies, leagues, and clubs globally, including FIFA, the International Olympic Committee, Formula 1, Bayern Munich, Ultimate Fighting Championship, NBA, World Rugby, and International Tennis Federation.

Getty Images has worked officially with UEFA since 2004 and has content from all UEFA club and national competitions since the first European Cup Final in 1956. For more information about Getty Images’ coverage of past and future UEFA tournaments, visit www.gettyimages.com/collections/uefa.

Media contact:

Gill Jones
[email protected]



Posted on

N2OFF Establishes a US Subsidiary for Its Solar PV Operations

T
he new entity
,
NITO Renewable Energy
, Inc.
, to hold all current and future
solar
operations of the
Company

Neve Yarak, Israel, March 03, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today the establishment of a new wholly-owned US subsidiary, NITO Renewable Energy, Inc., that is registered in Nevada. The new entity will focus and consolidate the Company’s current and future Solar PV activities.

The Company is currently invested in 3 projects in two countries in Europe.

Germany: The joint venture is developing a 111 MWp solar photovoltaic (PV) project in Melz, Germany. This project has secured municipal approval and an indicative grid connection solution from a regional energy service provider. Notably, the approved grid connection capacity exceeds initial requirements by approximately 10%, presenting opportunities to either increase the project’s capacity or integrate battery storage solutions. The project is currently progressing through the development phase.

Italy: N2OFF and Solterra’s subsidiary, Solterra Brand Services Italy, closed a definitive agreement to develop two Battery Energy Storage Systems (BESS) in Sicily, each with a capacity of 98 MWp/392 MWh. These projects have received approval for connection capacity from Terna SpA, Italy’s transmission system operator. Development is expected to take 18-24 months to reach a Ready-to-Build stage.

In addition, N2OFF and Solterra Energy Ltd. joined forces to exclusively co-develop the Solar PV market in Albania.

About N2OFF Inc:

N2OFF, Inc. (formerly known as Save Foods, Inc.) is a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech. Through its operational activities it delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions for the agri- tech market. NTWO OFF Ltd., N2OFF’s majority-owned Israeli subsidiary, aims to contribute in tackling greenhouse gas emissions, offering a pioneering solution to mitigate nitrous oxide (N2O) emissions, a potent greenhouse gas with 310 times the global warming impact of carbon dioxide. NTWO OFF Ltd., aims to promote agricultural practices that are both environmentally friendly and economically viable. N2OFF recently entered the solar PV market and will provide funding to Solterra Renewable Energy Ltd. for the current project in the total Capacity of 111 MWp, as well as potential future projects. Save Foods Ltd., N2OFF’s majority-owned Israeli subsidiary, focuses on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination. N2OFF also has a minority ownership in Plantify Foods, Inc., a Canadian company listed on the TSXV that offers a wide range of clean-label healthy food options. For more information on Save Foods Ltd. and NTWO OFF Ltd. visit our website: www.n2off.com.

Forward-looking Statements
:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties including the success of our collaboration with Solterra, entry into future projects, our ability to successfully enter the solar PV sector, the profitability of such industry, and the potential added value of the increased capacity. Actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including market conditions as well as those discussed under the heading “Risk Factors” in N2OFF’s Registration Statement on Form S-1/A filed with the SEC on February 14, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
[email protected]



Posted on

BRW Announces $0.085 Dividend

BRW Announces $0.085 Dividend

NEW YORK–(BUSINESS WIRE)–
Saba Capital Income & Opportunities Fund (NYSE: BRW) (the “Fund”), a registered closed-end management investment company listed on the New York Stock Exchange, declared a monthly dividend of $0.085 per share on February 28, 2025, payable on March 31, 2025 to shareholders of record as of March 11, 2025.

Managed Distribution Plan. The above distribution was declared in accordance with the Fund’s currently effective managed distribution plan (the “Plan”), whereby the Fund will make monthly distributions to shareholders at a fixed amount of $0.085 per share. Thus, the distribution amount shown excludes special dividends (which are not paid pursuant to the plan). The Fund will generally distribute amounts necessary to satisfy the Fund’s Plan and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. The Plan is intended to provide shareholders with a constant, but not guaranteed, fixed minimum rate of distribution each month and is intended to narrow the discount between the market price and the net asset value of the Fund’s common shares, but there is no assurance that the Plan will be successful in doing so.

Under the Plan, to the extent that sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital in order to maintain its managed distribution rate. As a result, long-term capital gains and/or return of capital may be a material source of any distribution. No conclusions should be drawn about the Fund’s investment performance from the amount of the Fund’s distributions or from the terms of the Fund’s Plan. The Board of Trustees (the “Board”) may amend the terms of the Plan or terminate the Plan at any time without prior notice to Fund shareholders. No level of distribution can be guaranteed. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s common shares. The Plan is subject to the periodic review by the Board, including a yearly review of the annual minimum fixed rate to determine if an adjustment should be made.

In compliance with Rule 19a-1 of the Investment Company Act of 1940, shareholders will receive a notice that details the source of income for the above dividend, such as net investment income, gain from the sale of securities and return of principal; however, determination of the actual source of the foregoing dividend can only be made at year-end. The actual source amounts of all Fund dividends will be included in the Fund’s annual or semiannual reports. In addition, the tax treatment may differ from the accounting treatment used to calculate the source of the Fund’s dividends as shown on shareholders’ statements. Shareholders should refer to their Form 1099-DIV for the character and amount of distributions for income tax reporting purposes. Since each shareholder’s tax situation is unique, it may be advisable to consult a tax advisor as to the appropriate treatment of Fund distributions.

Past Performance is No Assurance of Future Results. Investment return and principal value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. Investors should consider the investment objective, risks and expenses carefully. You can obtain the Fund’s most recent periodic reports and filings by visiting https://www.sec.gov/edgar/browse/?CIK=826020&owner=exclude.

Other Information and Certain Risk Factors: The Fund’s investment objective is to provide investors with a high level of current income, with a secondary goal of capital appreciation. There can be no assurance that the Fund will meet its investment objective. The Fund seeks to achieve this objective by investing globally in debt and equity securities of public and private companies, which includes, among other things, investments in closed‐end funds, special purpose acquisition companies (“SPACs”), reinsurance, and public and private debt instruments. The Fund also may utilize derivatives including but not limited to total return swaps, credit default swaps, options (including but not limited to index options) and futures, in seeking to enhance returns and/or to reduce portfolio risk. In addition, on an opportunistic basis, the Fund may also invest up to 15% of its total assets in private funds that focus on debt, equity or other investments consistent with the Fund’s investment objective.

The value of the Fund’s investments in equity securities of public and private, listed and unlisted companies and equity derivatives generally varies with the performance of the issuer and movements in the equity markets more generally. As a result, the Fund may suffer losses if it invests in equity instruments of issuers whose performance diverges from the Fund’s investment manager’s expectations or if equity markets generally move in a single direction and the Fund has not hedged against such a general move. The Fund may invest in closed-end funds and SPACs, which are subject to additional risks and considerations. The performance of reinsurance-related securities and the reinsurance industry itself are tied to the occurrence of various triggering events, including but not limited to weather, natural disasters (hurricanes, earthquakes, etc.), non-natural large catastrophes and other specified events causing physical and/or economic loss. To the extent the Fund invests in reinsurance-related securities for which a triggering event occurs, losses associated with such event could result in losses to the Fund’s investment, and a series of major triggering events affecting a large portion of the reinsurance- related securities held by the Fund could result in substantial losses to the Fund’s investment. The Fund may invest in high yield securities, which are speculative in nature and are subject to additional risk factors such as increased possibility of default, illiquidity of the security, and changes in value based on changes in interest rates. Changes in short-term market interest rates may directly affect the yield on the Fund’s common shares. If such rates fall, the Fund’s yield may also fall. If interest rate spreads on bonds and loans owned by the Fund decline in general, the yield on the bonds and loans will likely fall and the value of such bonds and loans may decrease. When short-term market interest rates rise, because of the lag between changes in such short-term rates and the resetting of the floating rates on bonds and loans in the Fund’s portfolio, the impact of rising rates will be delayed to the extent of such lag. Because of the limited secondary market for certain bonds and loans, the Fund’s ability to sell such securities in a timely fashion and/or at a favorable price may be limited. An increase in the demand for bonds and loans may adversely affect the rate of interest payable on new bonds and loans acquired by the Fund, and it may also increase the price of bonds and loans purchased by the Fund in the secondary market. A decrease in the demand for bonds and loans may adversely affect the price of bonds and loans in the Fund’s portfolio, which would cause the Fund’s net asset value to decrease. The Fund’s use of leverage, if any, through borrowings or issuance of preferred shares can adversely affect the yield on the Fund’s common shares. Investment in foreign borrowers involves special risks, including but not limited to potentially less rigorous accounting requirements, differing legal systems and potential political, social and economic adversity. The Fund may engage in currency exchange transactions to seek to hedge, as closely as practicable, all of the economic impact to the Fund arising from foreign currency fluctuations. Other risks include, but are not limited to, the use of derivatives, the potential lack of diversification in the Fund’s portfolio, and the fact that the Fund’s portfolio may be concentrated in a small group of industries or industry sectors from time to time. Investors should consult the Fund’s filings with the Securities and Exchange Commission as well as the materials on the Fund’s website for a more detailed discussion of these or other risk factors that affect the Fund.

About Saba Capital Income & Opportunities Fund. Saba Capital Income & Opportunities Fund is a publicly-traded registered closed-end management investment company. The Fund’s common shares trade on the New York Stock Exchange under the ticker symbol “BRW”. The Fund is managed by Saba Capital Management, L.P.

Forward-Looking Statements. This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including but not limited to statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors, including but not limited to the “Certain Risk Factors” noted above, are identified from time to time in the Fund’s filings with the Securities and Exchange Commission as well as the materials on the Fund’s website. The Fund undertakes no obligation to update such statements to reflect subsequent events, except as may be required by law.

For further information on Saba Capital Income & Opportunities Fund, please visit our website at: www.sabacef.com.

Contact: 844-460-9411

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Posted on

SABA Announces $0.058 Dividend

SABA Announces $0.058 Dividend

NEW YORK–(BUSINESS WIRE)–
Saba Capital Income & Opportunities Fund II (NYSE: SABA) (the “Fund”), a registered closed-end management investment company listed on the New York Stock Exchange, declared a monthly dividend of $0.058 per share on February 28, 2025, payable on March 31, 2025 to shareholders of record as of March 11, 2025.

Managed Distribution Plan. The above distribution was declared in accordance with the Fund’s currently effective managed distribution plan (the “Plan”), whereby the Fund will make monthly distributions to shareholders at a fixed amount of $0.058 per share. Thus, the distribution amount shown excludes special dividends (which are not paid pursuant to the plan). The Fund will generally distribute amounts necessary to satisfy the Fund’s Plan and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. The Plan is intended to provide shareholders with a constant, but not guaranteed, fixed minimum rate of distribution each month and is intended to narrow the discount between the market price and the net asset value of the Fund’s common shares, but there is no assurance that the Plan will be successful in doing so.

Under the Plan, to the extent that sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital in order to maintain its managed distribution rate. As a result, long-term capital gains and/or return of capital may be a material source of any distribution. No conclusions should be drawn about the Fund’s investment performance from the amount of the Fund’s distributions or from the terms of the Fund’s Plan. The Board of Trustees (the “Board”) may amend the terms of the Plan or terminate the Plan at any time without prior notice to Fund shareholders. No level of distribution can be guaranteed. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s common shares. The Plan is subject to the periodic review by the Board, including a yearly review of the annual minimum fixed rate to determine if an adjustment should be made.

In compliance with Rule 19a-1 of the Investment Company Act of 1940, shareholders will receive a notice that details the source of income for the above dividend, such as net investment income, gain from the sale of securities and return of principal; however, determination of the actual source of the foregoing dividend can only be made at year-end. The actual source amounts of all Fund dividends will be included in the Fund’s annual or semiannual reports. In addition, the tax treatment may differ from the accounting treatment used to calculate the source of the Fund’s dividends as shown on shareholders’ statements. Shareholders should refer to their Form 1099-DIV for the character and amount of distributions for income tax reporting purposes. Since each shareholder’s tax situation is unique, it may be advisable to consult a tax advisor as to the appropriate treatment of Fund distributions.

Past Performance is No Assurance of Future Results. Investment return and principal value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. Investors should consider the investment objective, risks and expenses carefully. You can obtain the Fund’s most recent periodic reports and filings by visiting https://www.sec.gov/edgar/browse/?CIK=828803&owner=exclude.

Other Information and Certain Risk Factors: The Fund’s investment objective is to provide investors with high current income, with a secondary goal of capital appreciation. There can be no assurance that the Fund will meet its investment objective. The Fund seeks to achieve this objective by investing globally in debt and equity securities of public and private companies, which includes, among other things, investments in closed‐end funds, special purpose acquisition companies (“SPACs”), reinsurance, and public and private debt instruments. The Fund also may utilize derivatives including but not limited to total return swaps, credit default swaps, options (including but not limited to index options) and futures, in seeking to enhance returns and/or to reduce portfolio risk. In addition, on an opportunistic basis, the Fund may also invest up to 15% of its total assets in private funds that focus on debt, equity or other investments consistent with the Fund’s investment objective.

The value of the Fund’s investments in equity securities of public and private, listed and unlisted companies and equity derivatives generally varies with the performance of the issuer and movements in the equity markets more generally. As a result, the Fund may suffer losses if it invests in equity instruments of issuers whose performance diverges from the Fund’s investment manager’s expectations or if equity markets generally move in a single direction and the Fund has not hedged against such a general move. The Fund may invest in closed-end funds and SPACs, which are subject to additional risks and considerations. The performance of reinsurance-related securities and the reinsurance industry itself are tied to the occurrence of various triggering events, including but not limited to weather, natural disasters (hurricanes, earthquakes, etc.), non-natural large catastrophes and other specified events causing physical and/or economic loss. To the extent the Fund invests in reinsurance-related securities for which a triggering event occurs, losses associated with such event could result in losses to the Fund’s investment, and a series of major triggering events affecting a large portion of the reinsurance- related securities held by the Fund could result in substantial losses to the Fund’s investment. The Fund may invest in high yield securities, which are speculative in nature and are subject to additional risk factors such as increased possibility of default, illiquidity of the security, and changes in value based on changes in interest rates. Changes in short-term market interest rates may directly affect the yield on the Fund’s common shares. If such rates fall, the Fund’s yield may also fall. If interest rate spreads on bonds and loans owned by the Fund decline in general, the yield on the bonds and loans will likely fall and the value of such bonds and loans may decrease. When short-term market interest rates rise, because of the lag between changes in such short-term rates and the resetting of the floating rates on bonds and loans in the Fund’s portfolio, the impact of rising rates will be delayed to the extent of such lag. Because of the limited secondary market for certain bonds and loans, the Fund’s ability to sell such securities in a timely fashion and/or at a favorable price may be limited. An increase in the demand for bonds and loans may adversely affect the rate of interest payable on new bonds and loans acquired by the Fund, and it may also increase the price of bonds and loans purchased by the Fund in the secondary market. A decrease in the demand for bonds and loans may adversely affect the price of bonds and loans in the Fund’s portfolio, which would cause the Fund’s net asset value to decrease. Investment in foreign borrowers involves special risks, including but not limited to potentially less rigorous accounting requirements, differing legal systems and potential political, social and economic adversity. The Fund may engage in currency exchange transactions to seek to hedge, as closely as practicable, all of the economic impact to the Fund arising from foreign currency fluctuations. Other risks include, but are not limited to, the use of derivatives, the potential lack of diversification in the Fund’s portfolio, and the fact that the Fund’s portfolio may be concentrated in a small group of industries or industry sectors from time to time. Investors should consult the Fund’s filings with the Securities and Exchange Commission as well as the materials on the Fund’s website for a more detailed discussion of these or other risk factors that affect the Fund.

About Saba Capital Income & Opportunities Fund II. Saba Capital Income & Opportunities Fund II is a publicly-traded registered closed-end management investment company. The Fund’s common shares trade on the New York Stock Exchange under the ticker symbol “SABA”. The Fund is managed by Saba Capital Management, L.P.

Forward-Looking Statements. This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including but not limited to statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors, including but not limited to the “Certain Risk Factors” noted above, are identified from time to time in the Fund’s filings with the Securities and Exchange Commission as well as the materials on the Fund’s website. The Fund undertakes no obligation to update such statements to reflect subsequent events, except as may be required by law.

For further information on Saba Capital Income & Opportunities Fund II, please visit our website at: www.sabacef.com.

Contact: 888-888-0319

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Posted on

Vimeo Launches Inaugural Short Film Grant in Partnership with Nikon and RED

Program provides up to $150,000 to support up-and-coming filmmakers and drive a new generation of talent

Submissions open March 10, Five winners selected by award-winning creators David Lowery, Charlotte Wells, Sean Wang, Savanah Leaf and Adam Bricker, ASC.

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — Vimeo, the world’s most innovative video experience platform for creators and enterprises, today announced the launch of the first-ever “Vimeo Short Film Grant presented by Nikon | RED.” This initiative will empower emerging filmmakers to bring their creative visions to life with the support and mentorship of industry visionaries, class-leading equipment, and distribution to Vimeo’s vast global audience.

The grant will award five filmmakers with $30,000 each in funding to produce a short film, along with one-on-one mentorship opportunities with the selection jury and the Vimeo Curation Team. Additionally, recipients will gain access to:

  • The latest Z CINEMA line of professional video equipment, including the V-RAPTOR [X] and KOMODO-X cinema cameras, which feature all-new Z mount options, as well as Nikon’s collection of award winning mirrorless cameras including the Z9, Z8 and Z6III – all powered by the innovative technology from Nikon and RED to ensure films are produced to the highest technical standards.1
  • A Vimeo Standard subscription, and distribution support on Vimeo.com –including dedicated promotion of their work at in-person screenings in NYC and LA hosted by Vimeo.

Winning projects will be selected by a prestigious jury of filmmakers, industry professionals, and Vimeo executives based on originality, artistic merit, and feasibility of project execution. The jury will be composed of celebrated Vimeo Staff Picks alumni, including filmmakers David Lowery, Charlotte Wells, Sean Wang, Savanah Leaf and cinematographer Adam Bricker, ASC.

“For two decades, Vimeo has served and inspired millions of filmmakers and film enthusiasts around the world,” said Philip Moyer, CEO of Vimeo. “We are incredibly proud to partner with industry leaders, Nikon and RED, on this new grant program to accelerate the future of storytelling and launch a new generation of filmmakers. Together we will provide filmmakers with resources, mentorship, and a trusted platform to create exceptional short films and connect with a global audience.”

“Short films are a form of their own, but they’re also an essential entryway into the feature film industry — a way many filmmakers begin to figure out what they’re doing and who they’re doing it with,” says filmmaker Charlotte Wells. “For years, Vimeo has given an impressive platform to short form work, supporting emerging filmmakers (including me), and in turn, I’m grateful to be able to support their inaugural short film grant — broadening access to this undeniably expensive art form.”

Filmmaker and grant program mentor Savannah Leaf added, “As a writer and director, the journey can often feel lonely and nerve-wracking. Mentorship is a powerful way to navigate those challenges, offering the support and confidence to create. From the start of my career, Vimeo has helped me build a community of peers and mentors. I’m excited to collaborate with Vimeo and emerging filmmakers to continue fostering the community that first gave me the courage to direct.”

“Nikon and RED are thrilled to partner with Vimeo on this important initiative, which recognizes the visions and talent of emerging filmmakers, while enabling them to create with the best tools available and expand to a broader audience than ever before,” said Naoki Onozato, President and CEO, of Nikon Inc. “We’re excited to see the incredible films that will be created through this grant.”

Keiji Oishi, CEO of RED Digital Cinema added, “Independent filmmaking is a vibrant community that amplifies fresh voices and unique stories, igniting creativity and innovation from emerging filmmakers. RED is excited to partner with Vimeo and Nikon in supporting these promising artists at the beginning of their cinematic journey, and we can’t wait to see what they create.”

Submissions for the “Vimeo Short Film Grant presented by Nikon | RED” will open on March 10, 2025. Winners will be notified by July 7, with projects to begin by July 2025. Filmmakers are encouraged to visit www.vimeo.com/shortfilmgrant for official rules, including eligibility, conditions, prize descriptions, and complete details.

About Vimeo:

Vimeo (NASDAQ: VMEO) is the world’s most innovative video experience platform. We enable anyone to create high-quality video experiences to better connect and bring ideas to life. We proudly serve our community of millions of users – from creative storytellers to globally distributed teams at the world’s largest companies – whose videos receive billions of views each month. Learn more at www.vimeo.com.

About Nikon:

Nikon Inc. is a world leader in digital imaging, precision optics and technologies for photo and video capture; globally recognized for setting new standards in product design and performance for an award-winning array of equipment that enables visual storytelling and content creation. Nikon Inc. distributes consumer and professional Z series mirrorless cameras, digital SLR cameras, a vast array of NIKKOR and NIKKOR Z lenses, Speedlights and system accessories, Nikon COOLPIX® compact digital cameras and Nikon software products. For more information, dial (800) NIKON-US or visitwww.nikonusa.com, which links all levels of photographers and visual storytellers to the Web’s most comprehensive learning and sharing communities. Connect with Nikon onFacebook,X,YouTube,Instagram,Threads, andTikTok.

About RED:

RED Digital Cinema is a leading manufacturer of professional digital cameras and accessories. In 2006, RED began a revolution with the 4K RED ONE digital cinema camera. By 2008, RED had released the DSMC (Digital Stills and Motion Camera) system that allowed the same camera to be used on award-winning features, television, commercials, music videos and magazine covers like “Vogue” and “Harper’s Bazaar.” Today, RED cameras are being used on some of the most lauded movies and episodics, including award winners “Mank,” “Squid Game,” “Hacks,” “Navalny,” “The Queen’s Gambit,” and “The Deepest Breath.” RED’s latest technology includes the highly advanced V-RAPTOR [X] and V-RAPTOR XL [X] systems, the flagship DSMC3 generation systems and the first available large format global shutter cinema cameras. The RED lineup also includes KOMODO-X and KOMODO, which features a global shutter sensor in a shockingly small and versatile form factor. Also available is RED Connect, a license-enabled feature that unlocks up to 8K 120FPS live cinematic streaming from the V-RAPTOR line of cameras. Find additional information atwww.RED.com.


1
 Equipment will be provided on a temporary loan basis, subject to availability and the final discretion of Nikon and RED.

Frank Filiatrault
[email protected]



Posted on

DEADLINE NEXT WEEK: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Contact the Firm Before March 10, 2025

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) — Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of purchasers of Regeneron securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”).

Investors that suffered losses from Regeneron (NASDAQ: REGN) investments can follow the link below for more information regarding the lawsuit:



CLICK HERE


to learn your rights.

Investors who purchased or acquired REGENERON securities during the Class Period may, no later than

MARCH 10, 2025

, seek to be appointed as a lead plaintiff representative of the class.

Regeneron, headquartered in Tarrytown, NY, is a biotechnology company that designs products for eye diseases, inflammatory diseases, cancer, and cardiovascular and metabolic diseases.

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of dollars in discounts provided to drug distributors in the form of reimbursed credit card fees.

As a result, the DOJ alleges that the average sales price of Regeneron’s Eylea drug was inflated, which inappropriately increased Medicare reimbursements.

On this news, the price of Regeneron shares declined by $31.50, more than 3%, over the next two trading days to close at $904.70 per share on April 12, 2024.

Then, on October 31, 2024, Regeneron announced that in Q3 2024, the Company’s sales had only increased 3% year-over-year, with quarterly sales of Eylea only $392 million, missing consensus estimates of $415 million to $425 million. The Company also revealed that sales of Eylea were “adversely impacted by a lower net selling price compared to the third quarter of 2023.”

On this news, Regeneron’s stock price fell $84.59, or 9%, to close at $838.20 per share on October 31, 2024.


For additional information or to learn how to participate in this litigation,




CLICK HERE




or please contact Berger Montague: Andrew Abramowitz at




[email protected]




or (215) 875-3015, or Peter Hamner at




[email protected]


.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.


Berger Montague
, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]  

Peter Hamner
Berger Montague PC
[email protected]



Date Total repurchased shares Weighted average price Total repurchased value
24-Feb-25 91,292 €709.97 €64,814,782
25-Feb-25 93,211 €695.35 €64,814,670
26-Feb-25 91,490 €708.43 €64,814,544
27-Feb-25 91,540 €708.04 €64,814,430
28-Feb-25 95,205 €680.79 €64,814,783

ASML’s current share buyback program was announced on 10 November 2022, and details are available on our website at https://www.asml.com/en/investors/why-invest-in-asml/share-buyback

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

Media Relations Contacts Investor Relations Contacts
Monique Mols, phone +31 6 528 444 18 Jim Kavanagh, phone +31 40 268 3938
  Pete Convertito, phone +1 203 919 1714
  Peter Cheang, phone +886 3 659 6771


 



Posted on

Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

~ Will Lead Audit Committee and Drive Orthopedics and Insurance Innovation ~

MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet”), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization.

Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Healthcare, driving transformative initiatives in Medicaid and Medicare Advantage demonstrating his deep experience in the insurance sector. Additionally, he is a seed investor and served as founding chief medical officer of VirtualHealth, a platform managing over 10 million lives, and co-founder and CEO of Fizio Health, an AI-powered remote physical therapy solution. With this dual expertise, Dr. Alleyne is uniquely positioned to provide strategic guidance to OneMedNet’s board in shaping innovative products tailored to the insurance and orthopedics sectors.

A graduate of Williams College, Dr. Alleyne completed his medical training at Wake Forest University, followed by residencies and fellowships at Howard University Hospital, Yale University, and the Harvard-MIT Division of Health Sciences and Technology.

“We are thrilled to welcome Dr. Alleyne to our board and as Chair of the Audit Committee,” said Jeffrey Yu, MD, Founder and Chairman of OneMedNet. “His proven leadership in healthcare innovation and insurance will supercharge OneMedNet’s mission. Ken’s vast orthopedic expertise will help us enhance our iRWD™ platform to deliver cutting-edge solutions, deepen ties with medical device leaders in the orthopedics space, and empower insurance companies with actionable insights and cost savings—particularly in orthopedics, a critical high-spend area.”

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: [email protected]

SOURCE: ONEMEDNET CORPORATION



Posted on

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company’s option

Proceeds from the royalty interest financing expected to fully fund U.S. commercial launch of taletrectinib

Pro forma cash balance expected to fully fund development of current clinical-stage pipeline and create a path to potential profitability without the need for additional fundraising; improves flexibility for opportunistic capital deployment

NEW YORK–(BUSINESS WIRE)–
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners (Sagard). The transaction comprises a royalty interest financing of $150 million and a senior term loan of up to $100 million. These financings strengthen Nuvation Bio’s balance sheet to fully fund commercialization of taletrectinib in the U.S., if approved, and development of the Company’s current clinical-stage pipeline. The transaction also provides Nuvation Bio with a path to potential profitability without the need to raise additional capital.

“This transaction is a significant milestone for Nuvation Bio as we prepare to bring taletrectinib to the U.S. market, subject to FDA approval, in mid-2025,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “With these financings, we are well positioned to launch taletrectinib and drive continued development of our clinical-stage pipeline—all without the need for additional fundraising. This also improves our flexibility to pursue strategic opportunities to deploy our capital. We are thrilled to have support from Sagard and appreciate their shared confidence in taletrectinib and Nuvation Bio as we continue toward our goal of improving outcomes for patients with cancer.”

Subject to the approval of taletrectinib by the U.S. Food and Drug Administration (FDA) on or prior to September 30, 2025, Sagard will provide Nuvation Bio with an upfront cash payment of $150 million. In return, Sagard will receive tiered royalties on U.S. net sales of taletrectinib, including 5.5% of annual U.S. net sales up to $600 million and 3.0% of annual U.S. net sales between $600 million and $1 billion. Nuvation Bio will retain all annual U.S. net sales above $1 billion. Payments to Sagard will cease upon the earliest occurrence of total royalties reaching 1.6 times its investment by June 30, 2031, 1.75 times its investment by June 30, 2034, or 2.0 times its investment thereafter.

“We are excited to partner with Nuvation Bio, an organization with deep oncology expertise and a commitment to delivering transformative therapies,” said Raja Manchanda, Partner at Sagard Healthcare Partners. “We believe taletrectinib has the potential to redefine the treatment landscape for patients with ROS1-positive non-small cell lung cancer, and we are pleased to provide a structured financing that supports both potential near-term commercialization and long-term growth.”

In addition to the royalty financing, Sagard has committed to a 5-year, senior secured term loan of up to $100 million, with $50 million to be funded upon U.S. FDA approval of taletrectinib on or prior to September 30, 2025. The second tranche of $50 million is available at Nuvation Bio’s option until June 30, 2026, as long as Nuvation Bio has achieved first U.S. commercial sale of taletrectinib. The term loan will bear interest at SOFR + 6.00%, subject to a 4.00% SOFR floor. There are no scheduled amortization payments associated with the term loan, with all outstanding principal due at maturity.

TD Cowen served as financial advisor and Cooley LLP served as legal advisor to Nuvation Bio. Sidley Austin LLP served as legal advisors to Sagard.

About Sagard

Sagard is a multi-strategy alternative asset management firm with over US$25B under management, 150 portfolio companies, and 400 professionals. Sagard invests in venture capital, private equity, private credit, and real estate. Sagard delivers flexible capital, an entrepreneurial culture, and a global network of investors, commercial partners, advisors, and value creation experts. Sagard’s dynamic and supportive ecosystem gives its partners the advantage they need to learn, grow and win at every stage. The firm has offices in Canada, the United States, Europe and the Middle East.

About Nuvation Bio

Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com or follow the Company on LinkedIn and X (@nuvationbioinc).

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, our expectations regarding U.S. FDA approval and commercial launch of taletrectinib, and the timing thereof, receipt and use of proceeds from the financings to fully fund U.S. commercial launch of taletrectinib and development of Nuvation Bio’s current clinical-stage pipeline, the path to potential profitability without need to raise additional capital, and the potential of taletrectinib to redefine the treatment landscape for patients with ROS1-positive non-small cell lung cancer. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on November 6, 2024, under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Nuvation Bio Investor Contact:

[email protected]

Nuvation Bio Media Contact:

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Oncology Professional Services Health Finance General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

ATTENTION NASDAQ: MPWR INVESTORS: Contact Berger Montague About a Monolithic Power Class Action Lawsuit

PHILADELPHIA, March 03, 2025 (GLOBE NEWSWIRE) — A securities class action lawsuit has been filed against MONOLITHIC POWER SYSTEMS, INC. (“Monolithic Power” or the “Company”) (NASDAQ: MPWR). The lawsuit has been filed on behalf of purchasers of Monolithic Power securities between February 8, 2024 and November 8, 2024, inclusive (the “Class Period”).



CLICK HERE


TO LEARN MORE ABOUT THIS LAWSUIT.


Investors who purchased or acquired

MONOLITHIC POWER

securities during the Class Period may, no later than


APRIL 7, 2025


, seek to be appointed as a lead plaintiff representative of the class.

Monolithic Power, headquartered in Kirkland, WA, is a provider of power management components used in electronic systems. Its largest customer is Nvidia Corporation, the world’s leading supplier of GPUs.

On November 11, 2024, Edgewater Research published a report revealing that Nvidia had cancelled half of its outstanding Monolithic Power orders and intended to eliminate Monolithic Power products in its next-generation Blackwell chips due to “[p]erformance issues.” The report further disclosed that Nvidia had “lost confidence” in Monolithic Power and had decided to turn to other suppliers.

On this news, the price of Monolithic Power shares fell $114 per share, or 15%, from a closing price of $761.30 per share on November 8, 2024 to a close of $647.31 per share on November 11, 2024.


For additional information or to learn how to participate in this litigation, please contact Berger Montague: Andrew Abramowitz at




[email protected]




or (215) 875-3015, or Peter Hamner at




[email protected]




, or




CLICK HERE


.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.


Berger Montague
, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contact:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]  

Peter Hamner
Berger Montague PC
[email protected]